Shanghai Junshi Biosciences’ Loqtorzi Approved in Singapore for Nasopharyngeal Carcinoma
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced receiving marketing approval from...
HKG: 1877
Shanghai Junshi Biosciences’ Loqtorzi Approved for Hepatocellular Carcinoma Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced receiving approval from the...
Junshi Biosciences Receives NMPA Approval for JS212 in Advanced Solid Tumors
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced receiving clearance from the...
Junshi Biosciences Receives NMPA Approval for JS213 Clinical Trials
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received...
Junshi Biosciences Licenses Toripalimab to LEO Pharma for EU and UK Markets
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced a licensing agreement...
Junshi Biosciences Forecasts 29.71% Revenue Growth for 2024
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has released its 2024 annual...
Junshi Biosciences’ Toripalimab Gains TGA Approval for Nasopharyngeal Carcinoma
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced receiving marketing approval...
Junshi Biosciences’ Mindewei Receives Full Approval in China
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that the conditional...
Junshi Biosciences’ Loqtorzi Gains Regular Approval for Melanoma Treatment in China
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that its PD-1 inhibitor,...
Shanghai Junshi Biosciences Enters Licensing Agreement for Dual-Targeted Fusion Proteins
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a China-based biopharmaceutical company, has announced...
Shanghai Junshi Biosciences’ Toripalimab Wins UK Approval for Nasopharyngeal and Oesophageal Cancers
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...
Junshi Biosciences Reports Q3 2024 Financials with Revenue Growth and Narrowed Losses
Junshi Biosciences (HKG: 1877; SHA: 688180) has released its financial results for the third quarter...
Shanghai Junshi Biosciences’ Toripalimab Wins Marketing Approvals in India and Hong Kong for Nasopharyngeal Carcinoma
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biotech company based in...
Junshi Biosciences’ Ongericimab Wins NMPA Nod for Hypercholesterolemia Treatment
Junshi Biosciences (HKG: 1877; SHA: 688180), a leading biopharmaceutical company in China, has announced that...
Shanghai Junshi Biosciences Inks Licensing Deal for IAMA-001 Nasal Spray with Nanjing JSIAMA
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a biopharmaceutical company based in China,...
Junshi Biosciences’ Toripalimab Secures EC Nod for Two Cancer Indications
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that it has received...
Junshi Biosciences Logs 17.37% Revenue Growth in 2024H1, Fueled by Loqtorzi Sales Surge
SHANGHAI—Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced its financial results for...
Junshi Biosciences Submits Twelfth Indication for PD-1 Inhibitor Loqtorzi in China
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced a new indication filing...
Junshi Biosciences’ Toripalimab Recommended for EU Approval for Two Indications
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has been recommended for approval by...
Junshi Biosciences’ Loqtorzi Inches Closer to Expanded Indication with NMPA Filing Acceptance
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has taken a significant step forward...